Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > National Cancer Institute (NCI) Contracts with Aphios to Develop Nannotech Combination Therapy for Certain Cancers

Abstract:
Aphios Corporation today announced that it has entered into a contract with the National Cancer Institute (NCI) to develop Tdp-1 inhibitors either as a primary therapy or in combination with camptothecins for colon, breast, ovarian, leukemia and other cancers. The contract was made through the Small Business Innovative Research (SBIR) Phase I program.

National Cancer Institute (NCI) Contracts with Aphios to Develop Nannotech Combination Therapy for Certain Cancers

Woburn, Massachusetts | Posted on April 8th, 2009

The contract is to develop a combination therapeutic based on research conducted by scientists at the National Cancer Institute who have discovered that the enzyme Tyrosyl-DNA phosphodiesterase (Tdp1) can repair topoisomerase I (Top1)-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond [US Patent Pending]. Inhibiting Tdp1 has the potential to enhance the anticancer activity of topoisomerase I inhibitors such as camptothecins and to act as anti-proliferative agents.

Dr. Yves Pommier, lead scientist of this invention at the NCI states that "The development of Tdp1 inhibitors as anticancer agents can be envisioned as combinations of Tdp1 and Top1 inhibitors. Moreover, Tdp1 inhibitors might also be effective by themselves as anticancer agents."

Scientists at Aphios are developing a co-encapsulation formulation of the selected camptothecin and Tdp1 inhibitor in phospholipid nanosomes (small, uniform liposomes). Camptothecins are quite hydrophobic and will be packaged in the lipid bilayer. Tdp1 inhibitors such as tetracycline and neomycin are quite water-soluble and will be packaged in the aqueous core of phospholipid nanosomes [US Patents and US Patent Pending].
We anticipate that this nanosomal formulation will result in reduced systemic toxicity, due to the masking of the cytotoxic effects of camptothecins and Tdp1 inhibitors. Additionally, the stability of the lactone ring in the nanosomes will be improved as a result of protection from the neutral pH of the blood stream. By increasing residence time in the circulatory system, the nanosomes increase therapeutic efficacy of the combination drugs. Optionally, pegylated phospholipids will be utilized to provide steric hindrance that will further increase residence time and therapeutic efficacy as is done with Doxil®, liposome encapsulated doxorubicin. Furthermore, phospholipids linked with specific antibodies or ligands will be utilized to target the co-encapsulated camptothecin and Tdp1 inhibitor to specific cancers in the colon, lung or ovary. Such smart targeting will further reduce toxicities associated with both Top1 and Tdp1 inhibitors while increasing efficacy and therapeutic index.

The project described herein is supported by NCI Contract No. HHSN-261200800026C (NCI Control No. N43CM-2008-00026). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI and the National Institutes of Health.

####

About Aphios Corporation
Aphios Corporation is a biotechnology company that is developing enabling technology platforms including nanotechnology drug delivery platforms such as phospholipid nanosomes, biodegradable polymer nanospheres, and protein and crystal nanoparticles for the improved delivery of poorly water-soluble anticancer drugs, therapeutic proteins and siRNA molecules, as well as enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and CNS disorders.

For more information, please click here

Contacts:
Dr. Trevor P. Castor
President and CEO
Aphios Corporation
3-E Gill Street, New Boston Park
Woburn, Massachusetts 01801 USA
Tel: (001) (781) 932-6933
Fax: (001) (781) 932-6865

Copyright © Aphios Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Govt.-Legislation/Regulation/Funding/Policy

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Nanomedicine

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Announcements

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

'Back to the Future' inspires solar nanotech-powered clothing November 15th, 2016

2-D material a brittle surprise: Rice University researchers finds molybdenum diselenide not as strong as they thought November 14th, 2016

New Book by Nobel Laureate Tells Story of Chemistry’s New Field: Fraser Stoddart explains the mechanical bond and where it is taking scientists November 11th, 2016

Nanobiotechnology

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Making spintronic neurons sing in unison November 18th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project